Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has submitted an application for an initial public offering (IPO) and listing on the Hong Kong Stock Exchange [1] Group 1 - The application materials have been filed with the Hong Kong Stock Exchange [1] - The announcement has been published on the Hong Kong Stock Exchange's website [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (referred to as "Lanacheng"), has submitted application materials for an initial public offering (IPO) and listing on the main board of the Hong Kong Stock Exchange, with the information published on the exchange's website [1] Group 1 - Dongcheng Pharmaceutical's subsidiary Lanacheng is pursuing an IPO in Hong Kong [1] - The application materials have been officially submitted to the Hong Kong Stock Exchange [1] - The announcement has been made public through the exchange's website [1]

证券代码：002675 证券简称：东诚药业 公告编号：2025-065 烟台东诚药业集团股份有限公司 关于分拆所属子公司烟台蓝纳成生物技术股份有限公司至 香港联合交易所有限公司主板上市的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本次分拆上市事项的进展情况 2025 年 9 月 29 日，公司收到蓝纳成的通知，蓝纳成于当日向香港联交所递 交了首次公开发行股票并在香港联交所主板上市的申请资料，且刊登于香港联交 所网站（www.hkexnews.hk）。 蓝纳成本次分拆上市的相关申请资料是按照香港证券及期货事务监察委员会 （以下简称"香港证监会"）和香港联交所的要求编制和刊发，为草拟版本，并未 定稿且所载资料可能会适时作出更新及修订。 三、风险提示 1 自分拆预案披露以来，公司稳步有序推进蓝纳成分拆上市的相关工作，截至 本公告发布日，本次分拆仍在推进过程中，尚需取得中国证监会、香港证监会、 香港联交所等有关监管机构批准，能否通过上述审核以及通过相关审核的时间均 存在不确定性，敬请广大投资者注意投资风险。公司将根据该事项的进展情况， 及时履行信息披 ...

Core Points - The company has signed a supplementary agreement to the shareholder agreement regarding its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd, in relation to its C-round financing [2][5][9] Group 1: C-Round Financing and Agreements - On February 14, 2025, the company approved a proposal for C-round financing for its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd [2] - Various stakeholders, including the founding shareholders and investment funds, signed the C-round investment agreement and shareholder agreement on February 25, 2025 [2] - The company agreed to repurchase all shares held by Shenzhen Jinglin Jingying Equity Investment Fund Partnership (Limited Partnership) on April 29, 2025, which corresponds to a registered capital of 1.466086 million [3] Group 2: Subsequent Investments and Agreements - On July 18, 2025, the company approved additional investments from several parties, including Yantai Blue Pharmaceutical Valley Construction Development Co., Ltd, to join the C-round investment agreement [4] - The company plans to spin off its subsidiary Lanacheng for a listing on the Hong Kong Stock Exchange, with board meetings held on August 28 and September 15, 2025, to approve related proposals [5] Group 3: Supplementary Agreement Details - The supplementary agreement states that certain rights and obligations under the C-round shareholder agreement will terminate upon the successful IPO of the target company [6] - If specific conditions regarding the IPO application are not met, the original terms of the C-round shareholder agreement will be reinstated [7] - The agreement clarifies that all parties have fulfilled their obligations under the C-round agreements and that there are no ongoing disputes or alternative arrangements [8]

证券代码：002675 证券简称：东诚药业 公告编号：2025-064 烟台东诚药业集团股份有限公司 关于控股子公司烟台蓝纳成生物技术股份有限公司 各方股东签署《股东协议的补充协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、签署《股东协议的补充协议》的基本情况 烟台东诚药业集团股份有限公司（以下简称 "东诚药业"或"公司"）于 2025 年 2 月 14 日第六届董事会第八次会议审议通过了《关于控股子公司增资扩 股引进投资者暨关联交易的议案》，同意公司控股子公司烟台蓝纳成生物技术股份 有限公司（以下简称"蓝纳成"或"目标公司"）以增资扩股方式进行 C 轮融资。2025 年 2 月 25 日，蓝纳成创始股东、A 轮投资方、B 轮投资方及深圳景林景盈股权 投资基金合伙企业（有限合伙）、B+轮投资方、C 轮初始投资方及目标公司共 同签署了《关于烟台蓝纳成生物技术股份有限公司之增资协议》（以下简称"《C 轮增资协议》"）及《关于烟台蓝纳成生物技术股份有限公司之股东协议》（以 下简称"《C 轮股东协议》"），约定了相关方投资目标公司及其享有的股东权 利 ...

Core Viewpoint - Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of the drug 225Ac-LNC1011, which targets advanced prostate cancer patients expressing Prostate Specific Membrane Antigen (PSMA) [1][2]. Drug Information - 225Ac-LNC1011 is an alpha-particle radioactive internal therapy drug targeting PSMA, designed for treating patients with advanced prostate cancer. Compared to traditional beta-particles, alpha-particles have a short range (<100 μm), high energy deposition (80-100 keV/μm), and multi-stage alpha decay, providing stronger cell-killing effects while minimizing damage to surrounding healthy tissues [1][2]. Clinical Trial and Development - The drug has shown excellent pharmacokinetic properties and significant efficacy in completed animal and human trials, indicating its potential as a more effective PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no similar products available in the domestic or international markets, and no related sales data exists [2]. - The total research and development expenses for the 225Ac-LNC1011 project have reached approximately 14.53 million yuan [2].

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Group 1 - The core point of the article is that Dongcheng Pharmaceutical's subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration of China to conduct clinical trials for Ac-LNC1011 injection for prostate cancer [1] Group 2 - The clinical trial for Ac-LNC1011 injection will be initiated shortly [1]

Core Viewpoint - Dongcheng Pharmaceutical announced that Yantai Lanna Biotechnology Co., Ltd. received clinical trial approval from the National Medical Products Administration for the 225Ac-LNC1011 injection, a targeted α-particle radiotherapy drug for treating advanced prostate cancer patients expressing PSMA [1] Company Summary - The 225Ac-LNC1011 injection has shown good pharmacokinetic properties and significant efficacy in completed animal and human trials, demonstrating effectiveness and precision in treating metastatic castration-resistant prostate cancer (mCRPC) [1] - The total research and development investment for this project has reached approximately 14.53 million yuan [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for patients with advanced prostate cancer, particularly those with PSMA-positive expression [1] - The drug must undergo multiple phases of clinical trials and official reviews before it can be marketed and sold [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. received approval from the National Medical Products Administration of China for the clinical trial of Ac-LNC1011 injection, which will soon commence clinical trials [1] Group 1 - The product Ac-LNC1011 injection is a targeted alpha-particle radiotherapy drug aimed at treating patients with advanced prostate cancer expressing Prostate Specific Membrane Antigen (PSMA) [1] - Alpha particles have a shorter range compared to traditional particles, which may enhance the treatment's effectiveness [1]